vs

Side-by-side financial comparison of Mativ Holdings, Inc. (MATV) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $463.1M, roughly 1.1× Mativ Holdings, Inc.). Mativ Holdings, Inc. runs the higher net margin — 21.8% vs 6.8%, a 14.9% gap on every dollar of revenue. On growth, Mativ Holdings, Inc. posted the faster year-over-year revenue change (1.0% vs -1.7%). Over the past eight quarters, Pediatrix Medical Group, Inc.'s revenue compounded faster (-0.1% CAGR vs -3.8%).

Mativ Holdings, Inc. is a global specialty materials manufacturer producing high-performance advanced polymers, nonwovens, filtration solutions, and functional coated materials. It serves healthcare, industrial, consumer goods, aerospace, and energy segments, with operations across North America, Europe, and Asia Pacific.

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

MATV vs MD — Head-to-Head

Bigger by revenue
MD
MD
1.1× larger
MD
$493.8M
$463.1M
MATV
Growing faster (revenue YoY)
MATV
MATV
+2.7% gap
MATV
1.0%
-1.7%
MD
Higher net margin
MATV
MATV
14.9% more per $
MATV
21.8%
6.8%
MD
Faster 2-yr revenue CAGR
MD
MD
Annualised
MD
-0.1%
-3.8%
MATV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MATV
MATV
MD
MD
Revenue
$463.1M
$493.8M
Net Profit
$100.8M
$33.7M
Gross Margin
18.8%
Operating Margin
2.2%
9.9%
Net Margin
21.8%
6.8%
Revenue YoY
1.0%
-1.7%
Net Profit YoY
6620.0%
10.5%
EPS (diluted)
$1.87
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MATV
MATV
MD
MD
Q4 25
$463.1M
$493.8M
Q3 25
$513.7M
$492.9M
Q2 25
$525.4M
$468.8M
Q1 25
$484.8M
$458.4M
Q4 24
$458.6M
$502.4M
Q3 24
$498.5M
$511.2M
Q2 24
$523.8M
$504.3M
Q1 24
$500.2M
$495.1M
Net Profit
MATV
MATV
MD
MD
Q4 25
$100.8M
$33.7M
Q3 25
$-3.2M
$71.7M
Q2 25
$-9.5M
$39.3M
Q1 25
$-425.5M
$20.7M
Q4 24
$1.5M
$30.5M
Q3 24
$-20.8M
$19.4M
Q2 24
$-1.4M
$-153.0M
Q1 24
$-28.0M
$4.0M
Gross Margin
MATV
MATV
MD
MD
Q4 25
18.8%
Q3 25
19.3%
Q2 25
19.7%
Q1 25
15.0%
Q4 24
16.9%
Q3 24
18.8%
Q2 24
20.8%
Q1 24
16.8%
Operating Margin
MATV
MATV
MD
MD
Q4 25
2.2%
9.9%
Q3 25
3.1%
13.8%
Q2 25
3.8%
12.8%
Q1 25
-88.8%
7.0%
Q4 24
0.6%
7.8%
Q3 24
1.4%
6.6%
Q2 24
2.0%
-31.3%
Q1 24
-2.8%
3.2%
Net Margin
MATV
MATV
MD
MD
Q4 25
21.8%
6.8%
Q3 25
-0.6%
14.5%
Q2 25
-1.8%
8.4%
Q1 25
-87.8%
4.5%
Q4 24
0.3%
6.1%
Q3 24
-4.2%
3.8%
Q2 24
-0.3%
-30.3%
Q1 24
-5.6%
0.8%
EPS (diluted)
MATV
MATV
MD
MD
Q4 25
$1.87
$0.40
Q3 25
$-0.06
$0.84
Q2 25
$-0.18
$0.46
Q1 25
$-7.82
$0.24
Q4 24
$0.03
$0.37
Q3 24
$-0.38
$0.23
Q2 24
$-0.03
$-1.84
Q1 24
$-0.52
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MATV
MATV
MD
MD
Cash + ST InvestmentsLiquidity on hand
$84.2M
$375.2M
Total DebtLower is stronger
$1.0B
$570.5M
Stockholders' EquityBook value
$498.7M
$865.9M
Total Assets
$2.1B
$2.2B
Debt / EquityLower = less leverage
2.07×
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MATV
MATV
MD
MD
Q4 25
$84.2M
$375.2M
Q3 25
$97.1M
$340.1M
Q2 25
$95.6M
$224.7M
Q1 25
$84.0M
$99.0M
Q4 24
$94.3M
$229.9M
Q3 24
$162.2M
$103.8M
Q2 24
$133.4M
$19.4M
Q1 24
$128.9M
$8.0M
Total Debt
MATV
MATV
MD
MD
Q4 25
$1.0B
$570.5M
Q3 25
$1.0B
$577.2M
Q2 25
$1.1B
$583.9M
Q1 25
$1.1B
$590.5M
Q4 24
$1.1B
$597.1M
Q3 24
$1.2B
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
MATV
MATV
MD
MD
Q4 25
$498.7M
$865.9M
Q3 25
$397.4M
$890.7M
Q2 25
$416.6M
$833.8M
Q1 25
$428.2M
$789.2M
Q4 24
$858.5M
$764.9M
Q3 24
$882.3M
$732.5M
Q2 24
$898.0M
$706.5M
Q1 24
$906.9M
$856.2M
Total Assets
MATV
MATV
MD
MD
Q4 25
$2.1B
$2.2B
Q3 25
$2.0B
$2.2B
Q2 25
$2.1B
$2.1B
Q1 25
$2.1B
$2.0B
Q4 24
$2.4B
$2.2B
Q3 24
$2.6B
$2.1B
Q2 24
$2.6B
$2.0B
Q1 24
$2.7B
$2.2B
Debt / Equity
MATV
MATV
MD
MD
Q4 25
2.07×
0.66×
Q3 25
2.63×
0.65×
Q2 25
2.66×
0.70×
Q1 25
2.67×
0.75×
Q4 24
1.30×
0.78×
Q3 24
1.32×
Q2 24
1.29×
Q1 24
1.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MATV
MATV
MD
MD
Operating Cash FlowLast quarter
$19.3M
$114.1M
Free Cash FlowOCF − Capex
$8.0M
FCF MarginFCF / Revenue
1.7%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
0.19×
3.39×
TTM Free Cash FlowTrailing 4 quarters
$93.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MATV
MATV
MD
MD
Q4 25
$19.3M
$114.1M
Q3 25
$72.8M
$137.3M
Q2 25
$57.6M
$137.2M
Q1 25
$-15.9M
$-117.5M
Q4 24
$24.1M
$133.0M
Q3 24
$37.6M
$91.8M
Q2 24
$46.1M
$107.0M
Q1 24
$-13.0M
$-125.2M
Free Cash Flow
MATV
MATV
MD
MD
Q4 25
$8.0M
Q3 25
$66.7M
Q2 25
$48.9M
Q1 25
$-29.8M
Q4 24
$2.0M
Q3 24
$25.5M
Q2 24
$37.4M
Q1 24
$-25.1M
FCF Margin
MATV
MATV
MD
MD
Q4 25
1.7%
Q3 25
13.0%
Q2 25
9.3%
Q1 25
-6.1%
Q4 24
0.4%
Q3 24
5.1%
Q2 24
7.1%
Q1 24
-5.0%
Capex Intensity
MATV
MATV
MD
MD
Q4 25
2.4%
Q3 25
1.2%
Q2 25
1.7%
Q1 25
2.9%
Q4 24
4.8%
Q3 24
2.4%
Q2 24
1.7%
Q1 24
2.4%
Cash Conversion
MATV
MATV
MD
MD
Q4 25
0.19×
3.39×
Q3 25
1.91×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
16.07×
4.36×
Q3 24
4.72×
Q2 24
Q1 24
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MATV
MATV

Other$208.7M45%
SAS Segment$157.4M34%
FAM Segment$97.0M21%

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons